Contributions
Abstract: EP1409
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Clinical assessment tools
Background: There is high enthusiasm for creating precision medicine tools to deliver more effective and personalized care for multiple sclerosis (MS). A plethora of tools and devices (often commercially-driven) are available but with unproven effectiveness. Further challenges, in the USA, include insurance and privacy regulations limiting the integration of these data in healthcare settings. To tackle these challenges, the UCSF MS BioScreen was created in 2014. Since then, technological and regulatory changes and user experience feedback, have substantially refined its scope.
Objective: To qualitatively describe the iterative testing and refinement of an innovative digital health tool within diverse and specific healthcare settings.
Methods: The original tablet-based BioScreen was developed to track, visualize, contextualize, predict and improve MS course. In an iterative process, we (1) tested feasibility and efficacy of deploying this tablet-based tool vs. usual care in 100 UCSF MS Center patient visits; (2) performed >75 interviews with stakeholders (patients, support groups, clinicians, scientists, MS societies, healthcare leaders, pharmaceutical and technology companies) to evaluate use cases; then (3) partnered with healthcare, institutional, governmental and non-profit stakeholders to develop next versions of the BioScreen.
Results: There was strong stakeholder enthusiasm for the BioScreen. Patients and clinicians prioritized integration at the point of care, leading the BioScreen to target three distinct populations. In the diverse N. Californian Sutter Health system, MS-Share launches from the EPIC EMR, and focuses on delivery of comprehensive care. Within the academic UCSF MS Center, the BioScreen launches from EPIC and pulls both EMR data and advanced metrics from research environments. For patients outside these health systems, the Open MS Bioscreen is a free online tool that can function as an MS-specific portable medical chart.
Conclusions: We describe the adaptation of BioScreen to varying clinical settings and unfolding regulatory requirements, illustrating both the challenges and opportunities in deploying precision medicine tools at the point of care. Future studies will focus on the tool's impact on care value.
Disclosure: R. Bove has served as consultant for Roche Genentech, Genzyme Sanofi, Novartis and received research support from Akili Interactive.
ES, PAG, JVL, KR, SS: nothing to disclose.
AL works for Alan.
CB, JBJ, WFS work for Sutter.
SLH serves on the scientific advisory boards for Symbiotix, Annexon, Bionure, and Molecular Stethoscope; board of trustees for Neurona, and also reports receiving travel reimbursement and writing assistance from F. Hoffmann-La Roche for CD20-related meetings and presentations.
Abstract: EP1409
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Clinical assessment tools
Background: There is high enthusiasm for creating precision medicine tools to deliver more effective and personalized care for multiple sclerosis (MS). A plethora of tools and devices (often commercially-driven) are available but with unproven effectiveness. Further challenges, in the USA, include insurance and privacy regulations limiting the integration of these data in healthcare settings. To tackle these challenges, the UCSF MS BioScreen was created in 2014. Since then, technological and regulatory changes and user experience feedback, have substantially refined its scope.
Objective: To qualitatively describe the iterative testing and refinement of an innovative digital health tool within diverse and specific healthcare settings.
Methods: The original tablet-based BioScreen was developed to track, visualize, contextualize, predict and improve MS course. In an iterative process, we (1) tested feasibility and efficacy of deploying this tablet-based tool vs. usual care in 100 UCSF MS Center patient visits; (2) performed >75 interviews with stakeholders (patients, support groups, clinicians, scientists, MS societies, healthcare leaders, pharmaceutical and technology companies) to evaluate use cases; then (3) partnered with healthcare, institutional, governmental and non-profit stakeholders to develop next versions of the BioScreen.
Results: There was strong stakeholder enthusiasm for the BioScreen. Patients and clinicians prioritized integration at the point of care, leading the BioScreen to target three distinct populations. In the diverse N. Californian Sutter Health system, MS-Share launches from the EPIC EMR, and focuses on delivery of comprehensive care. Within the academic UCSF MS Center, the BioScreen launches from EPIC and pulls both EMR data and advanced metrics from research environments. For patients outside these health systems, the Open MS Bioscreen is a free online tool that can function as an MS-specific portable medical chart.
Conclusions: We describe the adaptation of BioScreen to varying clinical settings and unfolding regulatory requirements, illustrating both the challenges and opportunities in deploying precision medicine tools at the point of care. Future studies will focus on the tool's impact on care value.
Disclosure: R. Bove has served as consultant for Roche Genentech, Genzyme Sanofi, Novartis and received research support from Akili Interactive.
ES, PAG, JVL, KR, SS: nothing to disclose.
AL works for Alan.
CB, JBJ, WFS work for Sutter.
SLH serves on the scientific advisory boards for Symbiotix, Annexon, Bionure, and Molecular Stethoscope; board of trustees for Neurona, and also reports receiving travel reimbursement and writing assistance from F. Hoffmann-La Roche for CD20-related meetings and presentations.